Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

SML2460

Sigma-Aldrich

SK33

≥98% (HPLC)

Synonym(s):

3-[3,5-Bis(trifluoromethyl)phenoxy]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H13F9N2O3
CAS Number:
1928724-23-5
Molecular Weight:
500.31
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

OC(C(NC1=CC(C(F)(F)F)=C(C#N)C=C1)=O)(C)COC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2

InChI

1S/C20H13F9N2O3/c1-17(33,16(32)31-13-3-2-10(8-30)15(7-13)20(27,28)29)9-34-14-5-11(18(21,22)23)4-12(6-14)19(24,25)26/h2-7,33H,9H2,1H3,(H,31,32)

InChI key

VJIVKRQGSGBLFP-UHFFFAOYSA-N

Biochem/physiol Actions

SK33, a trifluoromethylated enobosarm analog, is a cell and brain penetrant, tissue selective and highly potent anti-androgen that reduces androgen receptor (AR) transcriptional activity. SK33 induces cell cycle arrest at G1 phase. It exhibits increased efficacy against acquired anti-androgen resistance prostate cancer cells.
cell and brain penetrant, tissue selective and highly potent anti-androgen that reduces androgen receptor (AR) transcriptional activity

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Salvatore Ferla et al.
Bioorganic & medicinal chemistry letters, 26(15), 3636-3640 (2016-06-16)
Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of
D Alwyn Dart et al.
Molecular cancer therapeutics, 17(9), 1846-1858 (2018-06-14)
Prostate cancer often develops antiandrogen resistance, possibly via androgen receptor (AR) mutations, which change antagonists to agonists. Novel therapies with increased anticancer activity, while overcoming current drug resistance are urgently needed. Enobosarm has anabolic effects on muscle and bone while

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service